hydroxyzine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| diphenylmethyl piperazine derivatives | 1400 | 68-88-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 75 | mg | O |
| 75 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 700 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.24 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 12, 1956 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 611.74 | 9.65 | 830 | 57699 | 145090 | 46482443 |
| Intentional overdose | 315.84 | 9.65 | 398 | 58131 | 64546 | 46562987 |
| Toxicity to various agents | 294.30 | 9.65 | 748 | 57781 | 211018 | 46416515 |
| Intentional self-injury | 285.31 | 9.65 | 239 | 58290 | 23927 | 46603606 |
| Pruritus | 226.00 | 9.65 | 742 | 57787 | 241610 | 46385923 |
| Urticaria | 216.64 | 9.65 | 465 | 58064 | 117427 | 46510106 |
| Drug abuse | 153.66 | 9.65 | 281 | 58248 | 63127 | 46564406 |
| Rheumatoid arthritis | 151.46 | 9.65 | 56 | 58473 | 240159 | 46387374 |
| Poisoning | 142.04 | 9.65 | 127 | 58402 | 13867 | 46613666 |
| Poisoning deliberate | 118.31 | 9.65 | 90 | 58439 | 7836 | 46619697 |
| Chronic spontaneous urticaria | 107.67 | 9.65 | 36 | 58493 | 505 | 46627028 |
| Respiratory arrest | 101.75 | 9.65 | 165 | 58364 | 33651 | 46593882 |
| Cardio-respiratory arrest | 99.48 | 9.65 | 227 | 58302 | 59642 | 46567891 |
| Electrocardiogram QT prolonged | 94.75 | 9.65 | 203 | 58326 | 51122 | 46576411 |
| Cardiac arrest | 93.26 | 9.65 | 287 | 58242 | 90112 | 46537421 |
| Anticholinergic syndrome | 85.87 | 9.65 | 43 | 58486 | 1763 | 46625770 |
| Treatment failure | 82.23 | 9.65 | 10 | 58519 | 93077 | 46534456 |
| Suicide attempt | 74.65 | 9.65 | 193 | 58336 | 54843 | 46572690 |
| Angioedema | 70.76 | 9.65 | 154 | 58375 | 39188 | 46588345 |
| Suicidal ideation | 66.71 | 9.65 | 188 | 58341 | 56194 | 46571339 |
| Joint swelling | 66.55 | 9.65 | 66 | 58463 | 166007 | 46461526 |
| Anxiety | 66.03 | 9.65 | 422 | 58107 | 181535 | 46445998 |
| Contraindicated product administered | 64.99 | 9.65 | 11 | 58518 | 79936 | 46547597 |
| Burning mouth syndrome | 61.27 | 9.65 | 22 | 58507 | 386 | 46627147 |
| Overdose | 56.90 | 9.65 | 266 | 58263 | 101713 | 46525820 |
| Somnolence | 54.31 | 9.65 | 359 | 58170 | 156162 | 46471371 |
| Drug dependence | 53.04 | 9.65 | 92 | 58437 | 19809 | 46607724 |
| Synovitis | 50.54 | 9.65 | 8 | 58521 | 61067 | 46566466 |
| Drug intolerance | 48.65 | 9.65 | 68 | 58461 | 146981 | 46480552 |
| Chemical submission | 47.12 | 9.65 | 16 | 58513 | 236 | 46627297 |
| Bradypnoea | 46.44 | 9.65 | 35 | 58494 | 3004 | 46624529 |
| Irritability | 46.12 | 9.65 | 108 | 58421 | 28838 | 46598695 |
| Drug reaction with eosinophilia and systemic symptoms | 43.58 | 9.65 | 107 | 58422 | 29441 | 46598092 |
| Victim of chemical submission | 41.32 | 9.65 | 15 | 58514 | 272 | 46627261 |
| Prescription form tampering | 40.83 | 9.65 | 19 | 58510 | 661 | 46626872 |
| Rash maculo-papular | 38.04 | 9.65 | 98 | 58431 | 27776 | 46599757 |
| Allergy test positive | 35.56 | 9.65 | 14 | 58515 | 320 | 46627213 |
| Plasma cell myeloma | 34.26 | 9.65 | 7 | 58522 | 44471 | 46583062 |
| Coma | 33.85 | 9.65 | 154 | 58375 | 58195 | 46569338 |
| Hallucination, gustatory | 31.69 | 9.65 | 9 | 58520 | 70 | 46627463 |
| Scratch | 30.54 | 9.65 | 34 | 58495 | 4828 | 46622705 |
| Skin plaque | 30.30 | 9.65 | 37 | 58492 | 5798 | 46621735 |
| Faecal vomiting | 29.75 | 9.65 | 15 | 58514 | 624 | 46626909 |
| Drug screen positive | 29.38 | 9.65 | 30 | 58499 | 3861 | 46623672 |
| Hereditary angioedema | 28.68 | 9.65 | 35 | 58494 | 5481 | 46622052 |
| Mastocytosis | 28.63 | 9.65 | 13 | 58516 | 427 | 46627106 |
| Exposure via ingestion | 28.51 | 9.65 | 28 | 58501 | 3439 | 46624094 |
| Systemic lupus erythematosus | 28.34 | 9.65 | 24 | 58505 | 65156 | 46562377 |
| Eczema | 28.12 | 9.65 | 72 | 58457 | 20328 | 46607205 |
| Miosis | 27.96 | 9.65 | 38 | 58491 | 6619 | 46620914 |
| Psoriasis | 27.04 | 9.65 | 180 | 58349 | 78424 | 46549109 |
| Glossodynia | 26.82 | 9.65 | 11 | 58518 | 44362 | 46583171 |
| Intentional product misuse | 26.31 | 9.65 | 123 | 58406 | 47005 | 46580528 |
| Urticaria thermal | 25.78 | 9.65 | 8 | 58521 | 87 | 46627446 |
| Drug hypersensitivity | 25.01 | 9.65 | 437 | 58092 | 243388 | 46384145 |
| Agitation | 24.87 | 9.65 | 136 | 58393 | 55279 | 46572254 |
| Asphyxia | 24.83 | 9.65 | 32 | 58497 | 5294 | 46622239 |
| Therapeutic product effect decreased | 24.60 | 9.65 | 41 | 58488 | 82560 | 46544973 |
| Drug ineffective | 24.59 | 9.65 | 655 | 57874 | 677183 | 45950350 |
| Insomnia | 24.48 | 9.65 | 315 | 58214 | 164609 | 46462924 |
| Blood immunoglobulin E increased | 23.99 | 9.65 | 19 | 58510 | 1754 | 46625779 |
| Long QT syndrome | 23.71 | 9.65 | 24 | 58505 | 3056 | 46624477 |
| Arthropathy | 23.46 | 9.65 | 44 | 58485 | 84656 | 46542877 |
| Mixed liver injury | 23.31 | 9.65 | 24 | 58505 | 3119 | 46624414 |
| Abdominal discomfort | 23.17 | 9.65 | 104 | 58425 | 151061 | 46476472 |
| Altered state of consciousness | 23 | 9.65 | 73 | 58456 | 23275 | 46604258 |
| Alcoholism | 22.24 | 9.65 | 20 | 58509 | 2198 | 46625335 |
| Psychotic symptom | 22.24 | 9.65 | 14 | 58515 | 896 | 46626637 |
| Diet failure | 22.06 | 9.65 | 6 | 58523 | 39 | 46627494 |
| Hepatocellular injury | 21.88 | 9.65 | 84 | 58445 | 29438 | 46598095 |
| Decreased eye contact | 21.42 | 9.65 | 7 | 58522 | 91 | 46627442 |
| Labile hypertension | 20.98 | 9.65 | 11 | 58518 | 497 | 46627036 |
| Kounis syndrome | 20.98 | 9.65 | 15 | 58514 | 1187 | 46626346 |
| Mydriasis | 20.92 | 9.65 | 43 | 58486 | 10510 | 46617023 |
| Binge eating | 20.92 | 9.65 | 10 | 58519 | 370 | 46627163 |
| Depressed level of consciousness | 20.84 | 9.65 | 116 | 58413 | 47453 | 46580080 |
| Toxic skin eruption | 20.59 | 9.65 | 47 | 58482 | 12340 | 46615193 |
| Serotonin syndrome | 20.54 | 9.65 | 72 | 58457 | 24148 | 46603385 |
| Disturbance in attention | 20.35 | 9.65 | 86 | 58443 | 31474 | 46596059 |
| Nodular rash | 19.99 | 9.65 | 8 | 58521 | 191 | 46627342 |
| Interstitial lung disease | 19.84 | 9.65 | 23 | 58506 | 53926 | 46573607 |
| Lymphomatoid papulosis | 19.70 | 9.65 | 7 | 58522 | 119 | 46627414 |
| Panic attack | 19.68 | 9.65 | 63 | 58466 | 20179 | 46607354 |
| Perfume sensitivity | 19.54 | 9.65 | 11 | 58518 | 573 | 46626960 |
| Ventricular fibrillation | 19.53 | 9.65 | 44 | 58485 | 11452 | 46616081 |
| Atrial fibrillation | 19.23 | 9.65 | 66 | 58463 | 103524 | 46524009 |
| Urticaria chronic | 19.17 | 9.65 | 10 | 58519 | 447 | 46627086 |
| Eosinophilia | 18.85 | 9.65 | 60 | 58469 | 19157 | 46608376 |
| Pneumonia | 18.63 | 9.65 | 346 | 58183 | 375974 | 46251559 |
| Pancreatitis | 18.20 | 9.65 | 105 | 58424 | 43522 | 46584011 |
| Withdrawal syndrome | 18.14 | 9.65 | 57 | 58472 | 18077 | 46609456 |
| General physical health deterioration | 18.12 | 9.65 | 79 | 58450 | 115690 | 46511843 |
| Arthralgia | 18.12 | 9.65 | 335 | 58194 | 364268 | 46263265 |
| Aggression | 17.92 | 9.65 | 66 | 58463 | 22678 | 46604855 |
| Infusion related reaction | 17.78 | 9.65 | 66 | 58463 | 101142 | 46526391 |
| Akathisia | 17.18 | 9.65 | 33 | 58496 | 7681 | 46619852 |
| Respiratory depression | 17.09 | 9.65 | 42 | 58487 | 11558 | 46615975 |
| Hyperleukocytosis | 16.96 | 9.65 | 9 | 58520 | 417 | 46627116 |
| Maternal exposure during pregnancy | 16.65 | 9.65 | 69 | 58460 | 102480 | 46525053 |
| Hepatic enzyme increased | 16.65 | 9.65 | 50 | 58479 | 81737 | 46545796 |
| C-reactive protein increased | 16.61 | 9.65 | 30 | 58499 | 58560 | 46568973 |
| Congenital musculoskeletal anomaly | 16.55 | 9.65 | 9 | 58520 | 438 | 46627095 |
| Accidental overdose | 16.46 | 9.65 | 59 | 58470 | 20007 | 46607526 |
| Cholestasis | 16.36 | 9.65 | 72 | 58457 | 26821 | 46600712 |
| Pericarditis | 16.04 | 9.65 | 5 | 58524 | 23922 | 46603611 |
| Off label use | 15.61 | 9.65 | 360 | 58169 | 379481 | 46248052 |
| Renal impairment | 15.48 | 9.65 | 45 | 58484 | 74327 | 46553206 |
| Activation syndrome | 15.44 | 9.65 | 7 | 58522 | 229 | 46627304 |
| Accidental death | 15.43 | 9.65 | 15 | 58514 | 1820 | 46625713 |
| Derailment | 15.23 | 9.65 | 5 | 58524 | 66 | 46627467 |
| Depression | 15.03 | 9.65 | 298 | 58231 | 169806 | 46457727 |
| Dysarthria | 14.83 | 9.65 | 89 | 58440 | 37409 | 46590124 |
| Talipes | 14.73 | 9.65 | 13 | 58516 | 1394 | 46626139 |
| Neutropenia | 14.72 | 9.65 | 112 | 58417 | 143092 | 46484441 |
| Wrong technique in device usage process | 14.64 | 9.65 | 15 | 58514 | 1938 | 46625595 |
| Pleural effusion | 14.63 | 9.65 | 54 | 58475 | 82898 | 46544635 |
| Fat necrosis | 14.49 | 9.65 | 9 | 58520 | 563 | 46626970 |
| Anaemia | 14.30 | 9.65 | 230 | 58299 | 255549 | 46371984 |
| Formication | 14.27 | 9.65 | 21 | 58508 | 3935 | 46623598 |
| Pneumonitis | 14.25 | 9.65 | 9 | 58520 | 28411 | 46599122 |
| Temperature intolerance | 13.92 | 9.65 | 30 | 58499 | 7577 | 46619956 |
| Multiple fractures | 13.88 | 9.65 | 25 | 58504 | 5542 | 46621991 |
| Breast adenoma | 13.77 | 9.65 | 4 | 58525 | 34 | 46627499 |
| Cold agglutinins positive | 13.77 | 9.65 | 4 | 58525 | 34 | 46627499 |
| Tonsillar hypertrophy | 13.74 | 9.65 | 10 | 58519 | 814 | 46626719 |
| Photosensitivity reaction | 13.53 | 9.65 | 41 | 58488 | 12751 | 46614782 |
| Hypertriglyceridaemia | 13.44 | 9.65 | 25 | 58504 | 5679 | 46621854 |
| Burnout syndrome | 13.39 | 9.65 | 6 | 58523 | 191 | 46627342 |
| Superior sagittal sinus thrombosis | 13.37 | 9.65 | 10 | 58519 | 848 | 46626685 |
| Postural orthostatic tachycardia syndrome | 13.33 | 9.65 | 9 | 58520 | 649 | 46626884 |
| Red blood cell sedimentation rate increased | 13.31 | 9.65 | 6 | 58523 | 22883 | 46604650 |
| Lower respiratory tract infection | 13.24 | 9.65 | 31 | 58498 | 55058 | 46572475 |
| Nasal oedema | 13.23 | 9.65 | 10 | 58519 | 862 | 46626671 |
| Osteonecrosis | 13.12 | 9.65 | 8 | 58521 | 25736 | 46601797 |
| Sleep disorder | 13.10 | 9.65 | 102 | 58427 | 46693 | 46580840 |
| Wound | 12.97 | 9.65 | 21 | 58508 | 42781 | 46584752 |
| Retrograde amnesia | 12.96 | 9.65 | 7 | 58522 | 336 | 46627197 |
| Torsade de pointes | 12.90 | 9.65 | 39 | 58490 | 12115 | 46615418 |
| Affect lability | 12.85 | 9.65 | 30 | 58499 | 7990 | 46619543 |
| Gastrointestinal ischaemia | 12.70 | 9.65 | 6 | 58523 | 216 | 46627317 |
| Musculoskeletal stiffness | 12.40 | 9.65 | 72 | 58457 | 97921 | 46529612 |
| Cholecystitis chronic | 12.40 | 9.65 | 35 | 58494 | 10464 | 46617069 |
| Hypertonic bladder | 12.39 | 9.65 | 17 | 58512 | 2987 | 46624546 |
| Micrognathia | 12.35 | 9.65 | 6 | 58523 | 230 | 46627303 |
| Hallucination, olfactory | 12.35 | 9.65 | 6 | 58523 | 230 | 46627303 |
| Bruxism | 12.33 | 9.65 | 17 | 58512 | 3000 | 46624533 |
| Anaphylactic reaction | 12.33 | 9.65 | 111 | 58418 | 53001 | 46574532 |
| Eyelid haemangioma | 12.24 | 9.65 | 3 | 58526 | 12 | 46627521 |
| Hypercreatininaemia | 11.89 | 9.65 | 7 | 58522 | 397 | 46627136 |
| Bursitis | 11.86 | 9.65 | 5 | 58524 | 19837 | 46607696 |
| Gastrointestinal sounds abnormal | 11.77 | 9.65 | 18 | 58511 | 3488 | 46624045 |
| Herpes zoster meningoencephalitis | 11.74 | 9.65 | 6 | 58523 | 257 | 46627276 |
| Febrile neutropenia | 11.73 | 9.65 | 70 | 58459 | 94557 | 46532976 |
| Nasopharyngitis | 11.68 | 9.65 | 130 | 58399 | 153868 | 46473665 |
| Metabolic acidosis | 11.68 | 9.65 | 86 | 58443 | 38694 | 46588839 |
| Papule | 11.63 | 9.65 | 20 | 58509 | 4275 | 46623258 |
| Malignant neoplasm progression | 11.62 | 9.65 | 42 | 58487 | 64884 | 46562649 |
| Negative thoughts | 11.51 | 9.65 | 9 | 58520 | 816 | 46626717 |
| Granulomatous liver disease | 11.50 | 9.65 | 9 | 58520 | 817 | 46626716 |
| Drug withdrawal syndrome | 11.48 | 9.65 | 66 | 58463 | 27318 | 46600215 |
| Tachycardia | 11.45 | 9.65 | 182 | 58347 | 99440 | 46528093 |
| Apallic syndrome | 11.39 | 9.65 | 8 | 58521 | 615 | 46626918 |
| Haemoglobin decreased | 11.38 | 9.65 | 105 | 58424 | 128844 | 46498689 |
| Nightmare | 11.31 | 9.65 | 46 | 58483 | 16552 | 46610981 |
| Cardiac failure congestive | 11.30 | 9.65 | 68 | 58461 | 91682 | 46535851 |
| Dependence | 11.27 | 9.65 | 13 | 58516 | 1918 | 46625615 |
| Osteonecrosis of jaw | 11.27 | 9.65 | 16 | 58513 | 34386 | 46593147 |
| Therapeutic product effect incomplete | 11.24 | 9.65 | 55 | 58474 | 78098 | 46549435 |
| Vascular stent thrombosis | 11.08 | 9.65 | 9 | 58520 | 862 | 46626671 |
| Mucosal inflammation | 11.00 | 9.65 | 20 | 58509 | 38956 | 46588577 |
| Erythema marginatum | 10.96 | 9.65 | 3 | 58526 | 20 | 46627513 |
| Neuropathy peripheral | 10.86 | 9.65 | 68 | 58461 | 90825 | 46536708 |
| Occipital neuralgia | 10.85 | 9.65 | 6 | 58523 | 302 | 46627231 |
| Transverse sinus thrombosis | 10.77 | 9.65 | 8 | 58521 | 672 | 46626861 |
| Skin infection | 10.76 | 9.65 | 35 | 58494 | 11304 | 46616229 |
| Bipolar disorder | 10.59 | 9.65 | 26 | 58503 | 7151 | 46620382 |
| Electrocardiogram QRS complex prolonged | 10.56 | 9.65 | 22 | 58507 | 5427 | 46622106 |
| Pancytopenia | 10.50 | 9.65 | 63 | 58466 | 84995 | 46542538 |
| Generalised tonic-clonic seizure | 10.49 | 9.65 | 64 | 58465 | 27058 | 46600475 |
| Omphalitis | 10.39 | 9.65 | 4 | 58525 | 86 | 46627447 |
| Acarodermatitis | 10.36 | 9.65 | 8 | 58521 | 712 | 46626821 |
| Hair colour changes | 10.35 | 9.65 | 12 | 58517 | 1780 | 46625753 |
| Superior mesenteric artery syndrome | 10.22 | 9.65 | 4 | 58525 | 90 | 46627443 |
| Rash pustular | 10.12 | 9.65 | 25 | 58504 | 6904 | 46620629 |
| Infection | 10.04 | 9.65 | 113 | 58416 | 133479 | 46494054 |
| Alpha 2 globulin increased | 9.94 | 9.65 | 4 | 58525 | 97 | 46627436 |
| Post-traumatic stress disorder | 9.87 | 9.65 | 18 | 58511 | 4030 | 46623503 |
| Joint ankylosis | 9.76 | 9.65 | 7 | 58522 | 557 | 46626976 |
| Gastrointestinal haemorrhage | 9.71 | 9.65 | 57 | 58472 | 77316 | 46550217 |
| Injection site mass | 9.71 | 9.65 | 41 | 58488 | 14999 | 46612534 |
| Cerebral infarction | 9.68 | 9.65 | 9 | 58520 | 23357 | 46604176 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 483.27 | 10.58 | 544 | 29391 | 98948 | 29823595 |
| Toxicity to various agents | 328.49 | 10.58 | 613 | 29322 | 176570 | 29745973 |
| Drug abuse | 94.77 | 10.58 | 235 | 29700 | 81837 | 29840706 |
| Respiratory arrest | 90.39 | 10.58 | 128 | 29807 | 29130 | 29893413 |
| Poisoning | 89.46 | 10.58 | 81 | 29854 | 11301 | 29911242 |
| Pruritus | 85.48 | 10.58 | 286 | 29649 | 117918 | 29804625 |
| Coma | 82.10 | 10.58 | 146 | 29789 | 40303 | 29882240 |
| Intentional overdose | 81.99 | 10.58 | 148 | 29787 | 41333 | 29881210 |
| Cardio-respiratory arrest | 67.06 | 10.58 | 165 | 29770 | 57141 | 29865402 |
| Overdose | 58.20 | 10.58 | 201 | 29734 | 84136 | 29838407 |
| Suicidal behaviour | 58.04 | 10.58 | 28 | 29907 | 1334 | 29921209 |
| Urticaria | 54.37 | 10.58 | 148 | 29787 | 54458 | 29868085 |
| Parasomnia | 52.28 | 10.58 | 17 | 29918 | 277 | 29922266 |
| Ventricular tachyarrhythmia | 51.89 | 10.58 | 17 | 29918 | 284 | 29922259 |
| Hyperthermia | 51.81 | 10.58 | 57 | 29878 | 10042 | 29912501 |
| Bradypnoea | 51.67 | 10.58 | 29 | 29906 | 1892 | 29920651 |
| Exposure via ingestion | 48.34 | 10.58 | 31 | 29904 | 2580 | 29919963 |
| Cardiac arrest | 45.80 | 10.58 | 199 | 29736 | 92651 | 29829892 |
| Electrocardiogram QT prolonged | 39.60 | 10.58 | 101 | 29834 | 35734 | 29886809 |
| Toxic epidermal necrolysis | 37.98 | 10.58 | 66 | 29869 | 17874 | 29904669 |
| Drug reaction with eosinophilia and systemic symptoms | 37.60 | 10.58 | 86 | 29849 | 28402 | 29894141 |
| Intentional self-injury | 37.12 | 10.58 | 56 | 29879 | 13476 | 29909067 |
| Chemical submission | 34.84 | 10.58 | 8 | 29927 | 30 | 29922513 |
| Personal relationship issue | 31.77 | 10.58 | 10 | 29925 | 146 | 29922397 |
| Myocardial infarction | 29.61 | 10.58 | 50 | 29885 | 125575 | 29796968 |
| Febrile bone marrow aplasia | 27.35 | 10.58 | 37 | 29898 | 8060 | 29914483 |
| Eosinophilia | 27.16 | 10.58 | 65 | 29870 | 22095 | 29900448 |
| Electrocardiogram QRS complex prolonged | 27.05 | 10.58 | 27 | 29908 | 4250 | 29918293 |
| Shock | 26.90 | 10.58 | 66 | 29869 | 22793 | 29899750 |
| Somnolence | 26.81 | 10.58 | 177 | 29758 | 96586 | 29825957 |
| Dermatitis exfoliative | 26.61 | 10.58 | 35 | 29900 | 7421 | 29915122 |
| Anticholinergic syndrome | 26.49 | 10.58 | 14 | 29921 | 810 | 29921733 |
| Abnormal sleep-related event | 26.33 | 10.58 | 12 | 29923 | 502 | 29922041 |
| Face oedema | 25.71 | 10.58 | 43 | 29892 | 11291 | 29911252 |
| General physical health deterioration | 25.23 | 10.58 | 38 | 29897 | 99906 | 29822637 |
| Rash | 24.87 | 10.58 | 297 | 29638 | 191592 | 29730951 |
| Suspected suicide | 23.86 | 10.58 | 22 | 29913 | 3139 | 29919404 |
| Rheumatoid arthritis | 23.64 | 10.58 | 6 | 29929 | 41191 | 29881352 |
| Non-cardiogenic pulmonary oedema | 22.99 | 10.58 | 12 | 29923 | 677 | 29921866 |
| Bladder dilatation | 22.87 | 10.58 | 15 | 29920 | 1297 | 29921246 |
| Drug dependence | 22.47 | 10.58 | 59 | 29876 | 21236 | 29901307 |
| Dermatitis exfoliative generalised | 22.05 | 10.58 | 20 | 29915 | 2795 | 29919748 |
| Tachyphrenia | 20.70 | 10.58 | 13 | 29922 | 1043 | 29921500 |
| Sensory integrative dysfunction | 20.45 | 10.58 | 5 | 29930 | 26 | 29922517 |
| Emotional disorder of childhood | 20.29 | 10.58 | 5 | 29930 | 27 | 29922516 |
| Rash erythematous | 19.54 | 10.58 | 58 | 29877 | 22394 | 29900149 |
| Fixed eruption | 19.34 | 10.58 | 13 | 29922 | 1171 | 29921372 |
| Meningitis streptococcal | 18.60 | 10.58 | 5 | 29930 | 40 | 29922503 |
| Postural tremor | 18.57 | 10.58 | 8 | 29927 | 292 | 29922251 |
| Intentional product misuse | 18.38 | 10.58 | 76 | 29859 | 34591 | 29887952 |
| Clonus | 18.21 | 10.58 | 17 | 29918 | 2464 | 29920079 |
| Agitation | 18.17 | 10.58 | 104 | 29831 | 53969 | 29868574 |
| Tachycardia | 18.11 | 10.58 | 131 | 29804 | 73608 | 29848935 |
| Mumps | 18.00 | 10.58 | 6 | 29929 | 106 | 29922437 |
| Psoriasis | 17.88 | 10.58 | 87 | 29848 | 42419 | 29880124 |
| Mixed dementia | 17.60 | 10.58 | 7 | 29928 | 208 | 29922335 |
| Mental disorder | 17.08 | 10.58 | 40 | 29895 | 13409 | 29909134 |
| Alcoholism | 17.04 | 10.58 | 19 | 29916 | 3395 | 29919148 |
| Tremor | 16.88 | 10.58 | 131 | 29804 | 75232 | 29847311 |
| Agoraphobia | 16.86 | 10.58 | 7 | 29928 | 233 | 29922310 |
| Suicide attempt | 16.81 | 10.58 | 77 | 29858 | 36620 | 29885923 |
| Suicidal ideation | 16.71 | 10.58 | 76 | 29859 | 36038 | 29886505 |
| Drug ineffective | 16.63 | 10.58 | 240 | 29695 | 340147 | 29582396 |
| Eczema | 16.15 | 10.58 | 39 | 29896 | 13330 | 29909213 |
| Hypercapnic coma | 15.59 | 10.58 | 6 | 29929 | 163 | 29922380 |
| Victim of crime | 15.51 | 10.58 | 7 | 29928 | 286 | 29922257 |
| Atrial fibrillation | 15.30 | 10.58 | 56 | 29879 | 108068 | 29814475 |
| Disease progression | 15.19 | 10.58 | 36 | 29899 | 79838 | 29842705 |
| Faecal vomiting | 15.18 | 10.58 | 8 | 29927 | 460 | 29922083 |
| Neonatal respiratory distress | 15.18 | 10.58 | 8 | 29927 | 460 | 29922083 |
| Adrenergic syndrome | 15.18 | 10.58 | 5 | 29930 | 85 | 29922458 |
| Diarrhoea infectious | 15.15 | 10.58 | 8 | 29927 | 462 | 29922081 |
| Cerebral disorder | 14.85 | 10.58 | 15 | 29920 | 2395 | 29920148 |
| Accidental overdose | 14.77 | 10.58 | 46 | 29889 | 18229 | 29904314 |
| Injection site reaction | 14.76 | 10.58 | 33 | 29902 | 10727 | 29911816 |
| Administration related reaction | 14.76 | 10.58 | 5 | 29930 | 93 | 29922450 |
| Speech disorder developmental | 14.75 | 10.58 | 11 | 29924 | 1168 | 29921375 |
| Drug screen positive | 14.67 | 10.58 | 20 | 29915 | 4387 | 29918156 |
| Cardiac failure congestive | 14.54 | 10.58 | 40 | 29895 | 84367 | 29838176 |
| Echolalia | 14.44 | 10.58 | 6 | 29929 | 200 | 29922343 |
| Drug withdrawal syndrome | 14.32 | 10.58 | 48 | 29887 | 19761 | 29902782 |
| Pneumonia | 14.20 | 10.58 | 242 | 29693 | 334064 | 29588479 |
| Thyroiditis acute | 14.20 | 10.58 | 5 | 29930 | 105 | 29922438 |
| Prothrombin time ratio decreased | 14.08 | 10.58 | 7 | 29928 | 356 | 29922187 |
| Stereotypy | 14.00 | 10.58 | 8 | 29927 | 540 | 29922003 |
| Bicuspid aortic valve | 13.65 | 10.58 | 6 | 29929 | 230 | 29922313 |
| Generalised oedema | 13.64 | 10.58 | 34 | 29901 | 11851 | 29910692 |
| C-reactive protein increased | 13.61 | 10.58 | 14 | 29921 | 43459 | 29879084 |
| Priapism | 13.54 | 10.58 | 20 | 29915 | 4723 | 29917820 |
| Anxiety | 13.37 | 10.58 | 143 | 29792 | 89728 | 29832815 |
| Throat tightness | 13.36 | 10.58 | 25 | 29910 | 7167 | 29915376 |
| Dysuria | 13.21 | 10.58 | 51 | 29884 | 22490 | 29900053 |
| Adenoidectomy | 13.20 | 10.58 | 4 | 29931 | 51 | 29922492 |
| Miosis | 13.18 | 10.58 | 26 | 29909 | 7750 | 29914793 |
| Victim of homicide | 13.09 | 10.58 | 5 | 29930 | 133 | 29922410 |
| Respiratory failure | 13.03 | 10.58 | 54 | 29881 | 100588 | 29821955 |
| Disturbance in attention | 12.92 | 10.58 | 50 | 29885 | 22079 | 29900464 |
| Diarrhoea | 12.88 | 10.58 | 246 | 29689 | 333857 | 29588686 |
| Asphyxia | 12.86 | 10.58 | 21 | 29914 | 5404 | 29917139 |
| Meningioma | 12.79 | 10.58 | 11 | 29924 | 1432 | 29921111 |
| Anion gap | 12.78 | 10.58 | 8 | 29927 | 638 | 29921905 |
| Renal tubular disorder | 12.72 | 10.58 | 20 | 29915 | 4986 | 29917557 |
| Patient uncooperative | 12.69 | 10.58 | 5 | 29930 | 145 | 29922398 |
| Serotonin syndrome | 12.62 | 10.58 | 43 | 29892 | 17848 | 29904695 |
| Neurodevelopmental disorder | 12.25 | 10.58 | 5 | 29930 | 159 | 29922384 |
| Neurosis | 12.22 | 10.58 | 5 | 29930 | 160 | 29922383 |
| Cerebrovascular accident | 11.96 | 10.58 | 43 | 29892 | 83434 | 29839109 |
| Plasma cell myeloma | 11.93 | 10.58 | 22 | 29913 | 53440 | 29869103 |
| Dyskinesia | 11.67 | 10.58 | 48 | 29887 | 21786 | 29900757 |
| Erythrodermic psoriasis | 11.58 | 10.58 | 8 | 29927 | 754 | 29921789 |
| Bradycardia | 11.55 | 10.58 | 108 | 29827 | 65418 | 29857125 |
| Arthritis allergic | 11.51 | 10.58 | 3 | 29932 | 21 | 29922522 |
| Injection site mass | 11.51 | 10.58 | 19 | 29916 | 4934 | 29917609 |
| Kidney enlargement | 11.41 | 10.58 | 8 | 29927 | 772 | 29921771 |
| Pharyngeal dyskinesia | 11.39 | 10.58 | 3 | 29932 | 22 | 29922521 |
| Panic attack | 11.22 | 10.58 | 26 | 29909 | 8655 | 29913888 |
| Chronic spontaneous urticaria | 10.78 | 10.58 | 4 | 29931 | 98 | 29922445 |
| Acute myocardial infarction | 10.76 | 10.58 | 23 | 29912 | 52916 | 29869627 |
| Rash maculo-papular | 10.67 | 10.58 | 52 | 29883 | 25366 | 29897177 |
| Wrong patient received product | 10.63 | 10.58 | 11 | 29924 | 1806 | 29920737 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05BB01 | NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Diphenylmethane derivatives |
| ATC | N05BB51 | NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Diphenylmethane derivatives |
| FDA MoA | N0000000207 | Histamine Receptor Antagonists |
| FDA EPC | N0000175750 | Antihistamine |
| CHEBI has role | CHEBI:35474 | minor tranquilisers |
| CHEBI has role | CHEBI:37955 | h1-receptor blockers |
| CHEBI has role | CHEBI:50177 | dermatological agent |
| CHEBI has role | CHEBI:59683 | anti-itching drug |
| CHEBI has role | CHEBI:149553 | anti-coronaviral agents |
| MeSH PA | D000982 | Antipruritics |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D018494 | Histamine Agents |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006634 | Histamine H1 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dermatographic urticaria | indication | 7632005 | DOID:743 |
| Atopic dermatitis | indication | 24079001 | DOID:3310 |
| Allergic rhinitis | indication | 61582004 | |
| Nasal discharge | indication | 64531003 | |
| Urticaria | indication | 126485001 | |
| Itching of skin | indication | 418363000 | |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Severe Pruritus | off-label use | ||
| Tachyarrhythmia | contraindication | 6285003 | |
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Pulmonary edema | contraindication | 19242006 | DOID:11396 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Shock | contraindication | 27942005 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Acute hepatitis | contraindication | 37871000 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Third trimester pregnancy | contraindication | 41587001 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Multiple organ failure | contraindication | 57653000 | |
| Psychotic disorder | contraindication | 69322001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Cor pulmonale | contraindication | 83291003 | DOID:8515 |
| Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
| Seizure disorder | contraindication | 128613002 | |
| Cystic fibrosis | contraindication | 190905008 | DOID:1485 |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Sepsis syndrome | contraindication | 238150007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Continuous fever | contraindication | 271751000 | |
| Smoking cessation assistance | contraindication | 384742004 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Smokes tobacco daily | contraindication | 449868002 | |
| Severe Hypoxemia | contraindication | ||
| Theophylline Toxicity | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.53 | Basic |
| pKa2 | 3.53 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 8.70 | WOMBAT-PK | CHEMBL | |||
| Cytochrome P450 2D6 | Enzyme | Ki | 5.41 | WOMBAT-PK | |||||
| Envelope glycoprotein gp160 | Unclassified | IC50 | 5.20 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019782 | VUID |
| N0000147873 | NUI |
| D00672 | KEGG_DRUG |
| 2192-20-3 | SECONDARY_CAS_RN |
| 4017874 | VANDF |
| 4017875 | VANDF |
| 4019782 | VANDF |
| C0020404 | UMLSCUI |
| CHEBI:5818 | CHEBI |
| CHEMBL896 | ChEMBL_ID |
| CHEMBL1201007 | ChEMBL_ID |
| CHEMBL3186993 | ChEMBL_ID |
| CHEMBL1200467 | ChEMBL_ID |
| DB00557 | DRUGBANK_ID |
| D006919 | MESH_DESCRIPTOR_UI |
| 7199 | IUPHAR_LIGAND_ID |
| 599 | INN_ID |
| 30S50YM8OG | UNII |
| 3658 | PUBCHEM_CID |
| 154987 | RXNORM |
| 4857 | MMSL |
| 4858 | MMSL |
| 4859 | MMSL |
| 6478 | MMSL |
| 7094 | MMSL |
| d00907 | MMSL |
| 001451 | NDDF |
| 001452 | NDDF |
| 001453 | NDDF |
| 372856003 | SNOMEDCT_US |
| 80165005 | SNOMEDCT_US |
| 83933007 | SNOMEDCT_US |
| 83945003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vistaril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-5410 | CAPSULE | 25 mg | ORAL | NDA | 15 sections |
| Vistaril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-5420 | CAPSULE | 50 mg | ORAL | NDA | 15 sections |
| Vistaril | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-5440 | SUSPENSION | 25 mg | ORAL | NDA | 15 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5060 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5061 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5062 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1670 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1671 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1803 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1804 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-4822 | SYRUP | 10 mg | ORAL | ANDA | 14 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0613 | CAPSULE | 25 mg | ORAL | ANDA | 14 sections |
| hydroxyzine pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0615 | CAPSULE | 50 mg | ORAL | ANDA | 14 sections |
| hydroxyzine pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0674 | CAPSULE | 25 mg | ORAL | ANDA | 14 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1617 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 11 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4201 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-5601 | INJECTION, SOLUTION | 50 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-5602 | INJECTION, SOLUTION | 50 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-5610 | INJECTION, SOLUTION | 50 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0302 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0323 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0324 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8082 | TABLET | 25 mg | ORAL | ANDA | 12 sections |
| hydroxyzine pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8356 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
| hydroxyzine pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8357 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-0357 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-0358 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-0359 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6617 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 13 sections |
| Hydroxyzine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6618 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 13 sections |